Published in Brain Res on December 24, 1990
The effects of induced hypogonadism on arterial stiffness, body composition, and metabolic parameters in males with prostate cancer. J Clin Endocrinol Metab (2001) 2.61
A comparison of cabergoline and bromocriptine in the treatment of hyperprolactinemic amenorrhea. Cabergoline Comparative Study Group. N Engl J Med (1994) 2.58
Non-hepatic hyperammonaemia: an important, potentially reversible cause of encephalopathy. Postgrad Med J (2001) 2.14
Hyponatraemia, hypothyroidism, and role of arginine-vasopressin. Lancet (1997) 2.11
Trial of strategy for reducing the use of laboratory tests. Br Med J (Clin Res Ed) (1986) 1.82
Augmentation of central arterial pressure in mild primary hyperparathyroidism. J Clin Endocrinol Metab (2000) 1.82
Dopamine agonists and pituitary tumor shrinkage. Endocr Rev (1992) 1.67
Effects of bromocriptine on pituitary tumour size. Br Med J (1979) 1.64
Ovarian ultrasonography highlights precision of symptoms of ovulation as markers of ovulation. Br Med J (Clin Res Ed) (1986) 1.45
Venous thrombo-embolism following inferior petrosal sinus sampling in Cushing's disease. J Endocrinol Invest (2000) 1.44
Early-morning hyperglycemia in IDDM. Acute effects of cholinergic blockade. Diabetes Care (1989) 1.41
Body composition derived from whole body counting of potassium in growth hormone-deficient adults: a possible low intracellular potassium concentration. J Clin Endocrinol Metab (1996) 1.40
Diagnostic dilemmas in Cushing's syndrome. Ann Clin Biochem (2000) 1.39
Hypopituitarism after coronary artery bypass grafting. BMJ (1998) 1.39
Radioimmunoassay of brain-type creatine kinase-BB isoenzyme in human tissues and in serum of patients with neurological disorders. J Neurol Sci (1980) 1.25
Pseudohypercalcaemia in two patients with IgM paraproteinaemia. Ann Clin Biochem (1997) 1.20
Primary medical therapy for acromegaly: an open, prospective, multicenter study of the effects of subcutaneous and intramuscular slow-release octreotide on growth hormone, insulin-like growth factor-I, and tumor size. J Clin Endocrinol Metab (2002) 1.18
Differences in clinical and endocrine features between obese and non-obese subjects with polycystic ovary syndrome: an analysis of 263 consecutive cases. Clin Endocrinol (Oxf) (1990) 1.09
Reduction in size of a pituitary tumor by bromocriptine therapy. N Engl J Med (1979) 1.08
Long-term follow-up results of transsphenoidal surgery for Cushing's disease in a single centre using strict criteria for remission. Clin Endocrinol (Oxf) (2002) 1.08
Controversial aspects of thyroid disease. BMJ (1999) 1.07
Macroprolactin reactivities in prolactin assays: an issue for clinical laboratories and equipment manufacturers. Clin Chem (2000) 1.07
Effects of GH replacement on endothelial function and large-artery stiffness in GH-deficient adults: a randomized, double-blind, placebo-controlled study. Clin Endocrinol (Oxf) (2002) 1.06
Long-term remission following withdrawal of dopamine agonist therapy in subjects with microprolactinomas. Clin Endocrinol (Oxf) (2005) 1.04
Brachial plexus injury after median sternotomy. J Neurol Neurosurg Psychiatry (1981) 1.04
Management of selected patients with hyperprolactinaemia by partial hypophysectomy. Br Med J (Clin Res Ed) (1985) 1.03
Hypothyroid pituitary cells in culture: an analysis of thyrotropin and prolactin responses to dopamine (DA) and DA receptor binding. Endocrinology (1984) 1.01
Endothelial dysfunction in hypopituitary adults with growth hormone deficiency. Clin Endocrinol (Oxf) (1999) 1.00
Acromegaly and its treatment in the McCune-Albright syndrome. Clin Endocrinol (Oxf) (1992) 0.98
Pheochromocytoma in Pregnancy: When is Operative Intervention Indicated? J Womens Health (Larchmt) (2007) 0.98
Anticonvulsant therapy and cortisol elimination. Br J Clin Pharmacol (1985) 0.96
Comparison of long-acting analogues of luteinizing hormone releasing hormone in man. Clin Endocrinol (Oxf) (1979) 0.95
Transsphenoidal surgery for acromegaly in wales: results based on stringent criteria of remission. J Clin Endocrinol Metab (2003) 0.95
The effect of GH replacement therapy on endothelial function and oxidative stress in adult growth hormone deficiency. Eur J Endocrinol (2000) 0.95
The impact of guidelines in clinical outpatient practice. J R Coll Physicians Lond (1988) 0.95
Primary hypothyroidism presenting as amenorrhoea and galactorrhoea with hyperprolactinaemia and pituitary enlargement. Br Med J (Clin Res Ed) (1986) 0.93
Non-secretory adenomas of the pituitary treated by trans-ethmoidal sellotomy. J R Soc Med (1991) 0.93
Free fatty acids block growth hormone (GH) releasing hormone-stimulated GH secretion in man directly at the pituitary. J Clin Endocrinol Metab (1987) 0.92
Diagnostic value of thyrotrophin releasing hormone tests in elderly patients with atrial fibrillation. Br Med J (Clin Res Ed) (1985) 0.91
Altered dopaminergic regulation of thyrotrophin release in patients with prolactinomas: comparison with other tests of hypothalamic-pituitary function. Clin Endocrinol (Oxf) (1981) 0.91
HLA antigens and thyroid autoantibodies in patients with Graves' disease and their first degree relatives. Clin Endocrinol (Oxf) (1980) 0.91
Pituitary apoplexy following metastasis of bronchogenic adenocarcinoma to a prolactinoma. Clin Endocrinol (Oxf) (1999) 0.91
Thyrotropin-releasing hormone in the systemic circulation of the neonatal rat is derived from the pancreas and other extraneural tissues. J Clin Invest (1981) 0.90
McCune-Albright syndrome: growth hormone dynamics in pregnancy. J Clin Endocrinol Metab (2001) 0.89
Pituitary stone: two cases of densely calcified thyrotrophin-secreting pituitary adenomas. Clin Endocrinol (Oxf) (1994) 0.89
Prolactin response to thyrotropin-releasing hormone stimulation and dopaminergic inhibition in benign breast disease. Cancer (1984) 0.89
Increasing thyroxine requirements in primary hypothyroidism: don't forget the urinalysis! J Postgrad Med (2006) 0.88
Adenosine signalling pathways in the pituitary gland: one ligand, multiple receptors. J Endocrinol (2003) 0.88
Dopamine is a physiological regulator of thyrotrophin (TSH) secretion in normal man. Clin Endocrinol (Oxf) (1979) 0.88
Longer term outcome in females with congenital adrenal hyperplasia (CAH): the Cardiff experience. Clin Endocrinol (Oxf) (1997) 0.88
Thyrotropin regulates thyrotroph responsiveness to dopamine in vitro. Endocrinology (1986) 0.88
Radioiodine treatment in unsuspected pregnancy. Clin Endocrinol (Oxf) (1998) 0.86
Impaired vasoreactivity in bodybuilders using androgenic anabolic steroids. Eur J Clin Invest (2006) 0.86
The Miller Fischer syndrome following campylobacter enteritis: a report of two cases. J Neurol Neurosurg Psychiatry (1987) 0.86
Dopamine receptors on intact anterior pituitary cells in culture: functional association with the inhibition of prolactin and thyrotropin. Endocrinology (1983) 0.85
Hidradenitis suppurativa: evidence for an endocrine abnormality. Br J Surg (1985) 0.84
Immunoreactive aldolase C in cerebrospinal fluid of patients with neurological disorders. Ann Clin Biochem (1980) 0.84
Hyperprolactinaemia, amenorrhoea and galactorrhoea due to a pituitary thyrotroph adenoma. Clin Endocrinol (Oxf) (1985) 0.84
Thyrotropin response to thyrotropin-releasing hormone in elderly patients with and without acute illness. Age Ageing (1991) 0.83
Clinical value of immunoradiometric assay of thyrotropin for patients with nonthyroidal illness and taking various drugs. Clin Chem (1987) 0.83
Treatment of macroprolactinoma with cabergoline: a study of 85 patients. Clin Endocrinol (Oxf) (1997) 0.83
Altered responses of prolactin, luteinizing hormone and follicle stimulating hormone secretion to thyrotrophin releasing hormone/gonadotrophin releasing hormone stimulation in cyclical mastalgia. Br J Surg (1984) 0.83
Peripheral neuropathy during longterm high-dose amiodarone therapy. J Neurol Neurosurg Psychiatry (1985) 0.83
Adenosine-regulated cell proliferation in pituitary folliculostellate and endocrine cells: differential roles for the A(1) and A(2B) adenosine receptors. Endocrinology (2002) 0.82
Hypothyroidism: clinical features and complications. Clin Endocrinol Metab (1979) 0.82
Dopamine stimulates release of thyrotrophin-releasing hormone from perfused intact rat hypothalamus via hypothalamic D2-receptors. J Endocrinol (1987) 0.81
"Osler's phenomenon": misdiagnosing Cushing's syndrome. Postgrad Med J (2003) 0.81
Pituitary function with a solitary intrasellar plasmacytoma. Postgrad Med J (1985) 0.81
Thyroid status in senile dementia of the Alzheimer type (SDAT). Acta Psychiatr Scand (1987) 0.80
Thyroid-stimulating hormone: neuroregulation and clinical applications. Part 1. Clin Sci Mol Med (1978) 0.80
Some current aspects of clinical and experimental neuroendocrinology with particular reference to growth hormone, thyrotropin and prolactin. J Endocrinol Invest (1980) 0.80
Thyroid-stimulating hormone: neuroregulation and clinical applications. Part 2. Clin Sci Mol Med (1978) 0.80
Evidence for dopaminergic control of thyrotrophin secretion in man. Lancet (1977) 0.79
GH3 cells expressing constitutively active Gs alpha (Q227L) show enhanced hormone secretion and proliferation. Mol Cell Endocrinol (1997) 0.79
Growth hormone neuroregulation and its alterations in disease states. Clin Endocrinol (Oxf) (1988) 0.79
Non-adenomatous inappropriate TSH hypersecretion and euthyroidism requires no treatment. Clin Endocrinol (Oxf) (1987) 0.79
Long-term treatment of acromegaly with a long-acting analogue of somatostatin, octreotide. Q J Med (1990) 0.79
Preliminary characterization of growth factors secreted by human pituitary tumors. J Clin Endocrinol Metab (1991) 0.79
Effect of somatostatin on abnormal growth hormone and prolactin secretion in patients with the carcinoid syndrome. Clin Endocrinol (Oxf) (1979) 0.79
Low recurrence rate after partial hypophysectomy for prolactinoma: the predictive value of dynamic prolactin function tests. Clin Endocrinol (Oxf) (1992) 0.79
Hypokalaemia during insulin-induced hypoglycaemia in hypopituitary adults with and without growth hormone deficiency. Clin Endocrinol (Oxf) (1998) 0.79
Recovery of growth hormone secretion following cabergoline treatment of macroprolactinomas. Clin Endocrinol (Oxf) (2000) 0.78
The effects of thyroid hormone deprivation in vivo and in vitro on growth hormone (GH) responses to human pancreatic (tumor) GH-releasing factor (1-40) by dispersed rat anterior pituitary cells. Endocrinology (1985) 0.78
Prolactinomas. Br Med J (Clin Res Ed) (1985) 0.78
Growth factors and pituitary tumors. Trends Endocrinol Metab (2008) 0.78
Effect of oral administration of melatonin on GH responses to GRF 1-44 in normal subjects. Clin Endocrinol (Oxf) (1987) 0.78
Danazol and benign intracranial hypertension. Br Med J (Clin Res Ed) (1987) 0.78
Cholinergic muscarinic receptor blockade with pirenzepine abolishes slow wave sleep-related growth hormone release in normal adult males. Clin Endocrinol (Oxf) (1986) 0.78
Effects of hypothyroidism, tri-iodothyronine and glucocorticoids on growth hormone responses to growth hormone-releasing hormone and His-D-Trp-Ala-Trp-D-Phe-Lys-NH2. J Endocrinol (1989) 0.78
Dopaminergic modulation of circadian thyrotropin rhythms and thyroid hormone levels in euthyroid subjects. J Clin Endocrinol Metab (1980) 0.77
Effects of Glucose on Thyrotrophin-Releasing Hormone, Growth Hormone-Releasing Hormone, Somatostatin and Luteinizing Hormone-Releasing Hormone Release from Rat Hypothalamus in vitro. J Neuroendocrinol (1989) 0.77
Cholinergic muscarinic receptor blockade with pirenzepine abolishes slow wave sleep-related growth hormone release in young patients with insulin-dependent diabetes mellitus. Clin Endocrinol (Oxf) (1987) 0.77
Effect of oral glucose on the late growth hormone rise and growth hormone responses to GHRH in normal subjects. Clin Endocrinol (Oxf) (1990) 0.77
Additive effects of growth hormone releasing factor and insulin hypoglycaemia on growth hormone release in man. Clin Endocrinol (Oxf) (1987) 0.77
Growth hormone and its modulation. J R Coll Physicians Lond (1988) 0.77
Dopaminergic control of TSH secretion in isolated rat pituitary cells. FEBS Lett (1980) 0.77
Growth hormone releasing hormone 1-44 NH2 and 1-40 OH levels in normal subjects during growth hormone stimulation tests. Clin Endocrinol (Oxf) (1994) 0.77
Microprolactinoma: medical or surgical treatment as first line approach? The case for medical therapy. J Endocrinol Invest (2000) 0.77
Suppurative thyroiditis with oesophageal carcinoma. Postgrad Med J (1992) 0.77
Growth factors and the anterior pituitary. Baillieres Clin Endocrinol Metab (1991) 0.76